HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis
dc.contributor.author | Sun, Yuqing | |
dc.contributor.author | Zhou, Bo | |
dc.contributor.author | Mao, Fengbiao | |
dc.contributor.author | Xu, Jing | |
dc.contributor.author | Miao, Hongzhi | |
dc.contributor.author | Zou, Zhenhua | |
dc.contributor.author | Khoa, Le Tran Phuc | |
dc.contributor.author | Jang, Younghoon | |
dc.contributor.author | Cai, Sheng | |
dc.contributor.author | Witkin, Matthew | |
dc.contributor.author | Koche, Richard | |
dc.contributor.author | Ge, Kai | |
dc.contributor.author | Dressler, Gregory | |
dc.contributor.author | Levine, Ross L. | |
dc.contributor.author | Armstrong, Scott A. | |
dc.contributor.author | Dou, Yali | |
dc.contributor.author | Hess, Jay L. | |
dc.contributor.department | Pathology and Laboratory Medicine, School of Medicine | en_US |
dc.date.accessioned | 2020-01-03T19:41:03Z | |
dc.date.available | 2020-01-03T19:41:03Z | |
dc.date.issued | 2018-10-08 | |
dc.description.abstract | Aberrant expression of HOXA9 is a prominent feature of acute leukemia driven by diverse oncogenes. Here we show that HOXA9 overexpression in myeloid and B progenitor cells leads to significant enhancer reorganizations with prominent emergence of leukemia-specific de novo enhancers. Alterations in the enhancer landscape lead to activation of an ectopic embryonic gene program. We show that HOXA9 functions as a pioneer factor at de novo enhancers and recruits CEBPα and the MLL3/MLL4 complex. Genetic deletion of MLL3/MLL4 blocks histone H3K4 methylation at de novo enhancers and inhibits HOXA9/MEIS1-mediated leukemogenesis in vivo. These results suggest that therapeutic targeting of HOXA9-dependent enhancer reorganization can be an effective therapeutic strategy in acute leukemia with HOXA9 overexpression | en_US |
dc.eprint.version | Author's manuscript | en_US |
dc.identifier.citation | Sun, Y., Zhou, B., Mao, F., Xu, J., Miao, H., Zou, Z., … Hess, J. L. (2018). HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer cell, 34(4), 643–658.e5. doi:10.1016/j.ccell.2018.08.018 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/21723 | |
dc.language.iso | en_US | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.isversionof | 10.1016/j.ccell.2018.08.018 | en_US |
dc.relation.journal | Cancer Cell | en_US |
dc.rights | Publisher Policy | en_US |
dc.source | PMC | en_US |
dc.subject | HOXA9 | en_US |
dc.subject | KMT2 | en_US |
dc.subject | MLL | en_US |
dc.subject | Acute leukemia | en_US |
dc.subject | De novo enhancer | en_US |
dc.subject | Epigenetics | en_US |
dc.subject | Histone methylation | en_US |
dc.subject | Pioneer factor | en_US |
dc.subject | Transcription factor | en_US |
dc.title | HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis | en_US |
dc.type | Article | en_US |